التفاصيل البيبلوغرافية
| العنوان: |
Pharmacological and clinical profiles of avacopan (TAVNEOS® capsule), a selective C5a receptor antagonist. (English) |
| المؤلفون: |
Yuya Maruyama, Takumitsu Yoshida, Itaru Maruyama |
| المصدر: |
Folia Pharmacologica Japonica; 2023, Vol. 158 Issue 5, p399-407, 9p |
| مصطلحات موضوعية: |
ANTINEUTROPHIL cytoplasmic antibodies, MICROSCOPIC polyangiitis, KIDNEY physiology, GRANULOMATOSIS with polyangiitis, ECULIZUMAB, COMPLEMENT activation, GLUCOCORTICOIDS |
| مصطلحات جغرافية: |
JAPAN |
| مستخلص: |
Avacopan (TAVNEOS® capsules) is an orally available selective C5a receptor (C5aR) antagonist. It has been approved in Japan since 2021 for the treatment of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA), the two major subtypes of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The current standard therapy combining glucocorticoids (GC) and immunosuppressants has greatly improved the prognosis of AAV, however, issues such as side effects associated with GC use remain to be resolved. Avacopan suppresses priming of neutrophils induced by the complement component C5a, a process deeply involved in the pathogenesis of AAV. In pre-clinical studies, avacopan inhibited chemotaxis and priming of neutrophils induced by C5a-C5aR signaling. It also significantly suppressed nephritis and renal damage in an ANCA-induced glomerulonephritis mouse model. In the global phase 3 study "ADVOCATE", avacopan achieved both primary endpoints being 1) non-inferior to prednisone in inducing remission at week 26 and 2) superior in sustained remission at week 52 for MPA and GPA patients. Additionally, with avacopan, GC toxicity score was significantly lower and fewer adverse events possibly related to GC were observed. Furthermore, avacopan increased estimated glomerular filtration rate (eGFR) more than prednisone indicating improved renal function. Thus, the novel mechanism of avacopan targeting the complement system is a promising new therapeutic option for AAV with fewer GC-related side effects and better improvement of renal function. [ABSTRACT FROM AUTHOR] |
|
Copyright of Folia Pharmacologica Japonica is the property of Japanese Pharmacological Society and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
